261 related articles for article (PubMed ID: 33876843)
21. Regulation of c-Fos and Fra-1 by the MEK5-ERK5 pathway.
Terasawa K; Okazaki K; Nishida E
Genes Cells; 2003 Mar; 8(3):263-73. PubMed ID: 12622723
[TBL] [Abstract][Full Text] [Related]
22. Selective Cox-2 inhibitor celecoxib induces epithelial-mesenchymal transition in human lung cancer cells via activating MEK-ERK signaling.
Wang ZL; Fan ZQ; Jiang HD; Qu JM
Carcinogenesis; 2013 Mar; 34(3):638-46. PubMed ID: 23172668
[TBL] [Abstract][Full Text] [Related]
23. miR-122-5p promotes aggression and epithelial-mesenchymal transition in triple-negative breast cancer by suppressing charged multivesicular body protein 3 through mitogen-activated protein kinase signaling.
Wang Z; Wang X
J Cell Physiol; 2020 Mar; 235(3):2825-2835. PubMed ID: 31541468
[TBL] [Abstract][Full Text] [Related]
24. Activation of GPER suppresses epithelial mesenchymal transition of triple negative breast cancer cells via NF-κB signals.
Chen ZJ; Wei W; Jiang GM; Liu H; Wei WD; Yang X; Wu YM; Liu H; Wong CK; Du J; Wang HS
Mol Oncol; 2016 Jun; 10(6):775-88. PubMed ID: 26842883
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-1246 suppresses the metastasis of breast cancer cells by targeting the DYRK1A/PGRN axis to prevent the epithelial-mesenchymal transition.
Wang P; Chen W; Zhang Y; Zhong Q; Li Z; Wang Y
Mol Biol Rep; 2022 Apr; 49(4):2711-2721. PubMed ID: 35059968
[TBL] [Abstract][Full Text] [Related]
26. The WNK1-ERK5 route plays a pathophysiological role in ovarian cancer and limits therapeutic efficacy of trametinib.
Sánchez-Fdez A; Matilla-Almazán S; Montero JC; Del Carmen S; Abad M; García-Alonso S; Bhattacharya S; Calar K; de la Puente P; Ocaña A; Pandiella A; Esparís-Ogando A
Clin Transl Med; 2023 Apr; 13(4):e1217. PubMed ID: 37029785
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct downregulation of MCAM in triple-negative breast cancer cells.
Zeng D; Liang YK; Xiao YS; Wei XL; Lin HY; Wu Y; Bai JW; Chen M; Zhang GJ
Int J Cancer; 2020 Jul; 147(2):490-504. PubMed ID: 32020593
[TBL] [Abstract][Full Text] [Related]
28. Oncogenic signaling of MEK5-ERK5.
Hoang VT; Yan TJ; Cavanaugh JE; Flaherty PT; Beckman BS; Burow ME
Cancer Lett; 2017 Apr; 392():51-59. PubMed ID: 28153789
[TBL] [Abstract][Full Text] [Related]
29. BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Emery CM; Monaco KA; Wang P; Balak M; Freeman A; Meltzer J; Delach SM; Rakiec D; Ruddy DA; Korn JM; Haling J; Acker MG; Caponigro G
Mol Cancer Res; 2017 Oct; 15(10):1431-1444. PubMed ID: 28655712
[TBL] [Abstract][Full Text] [Related]
30. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
[TBL] [Abstract][Full Text] [Related]
31. Regulation of cancerous progression and epithelial-mesenchymal transition by miR-34c-3p via modulation of MAP3K2 signaling in triple-negative breast cancer cells.
Wu J; Li WZ; Huang ML; Wei HL; Wang T; Fan J; Li NL; Ling R
Biochem Biophys Res Commun; 2017 Jan; 483(1):10-16. PubMed ID: 28069384
[TBL] [Abstract][Full Text] [Related]
32. The Endosomal Protein CEMIP Links WNT Signaling to MEK1-ERK1/2 Activation in Selumetinib-Resistant Intestinal Organoids.
Duong HQ; Nemazanyy I; Rambow F; Tang SC; Delaunay S; Tharun L; Florin A; Büttner R; Vandaele D; Close P; Marine JC; Shostak K; Chariot A
Cancer Res; 2018 Aug; 78(16):4533-4548. PubMed ID: 29915160
[TBL] [Abstract][Full Text] [Related]
33. Fatty acid synthase mediates the epithelial-mesenchymal transition of breast cancer cells.
Li J; Dong L; Wei D; Wang X; Zhang S; Li H
Int J Biol Sci; 2014; 10(2):171-80. PubMed ID: 24520215
[TBL] [Abstract][Full Text] [Related]
34. Primary cross-resistance to BRAFV600E-, MEK1/2- and PI3K/mTOR-specific inhibitors in BRAF-mutant melanoma cells counteracted by dual pathway blockade.
Penna I; Molla A; Grazia G; Cleris L; Nicolini G; Perrone F; Picciani B; Del Vecchio M; de Braud F; Mortarini R; Anichini A
Oncotarget; 2016 Jan; 7(4):3947-65. PubMed ID: 26678033
[TBL] [Abstract][Full Text] [Related]
35. Luteolin suppresses epithelial-mesenchymal transition and migration of triple-negative breast cancer cells by inhibiting YAP/TAZ activity.
Cao D; Zhu GY; Lu Y; Yang A; Chen D; Huang HJ; Peng SX; Chen LW; Li YW
Biomed Pharmacother; 2020 Sep; 129():110462. PubMed ID: 32768952
[TBL] [Abstract][Full Text] [Related]
36. Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
Mandal R; Becker S; Strebhardt K
Oncogene; 2016 May; 35(20):2547-61. PubMed ID: 26364606
[TBL] [Abstract][Full Text] [Related]
37. Elevated TGF-β1 and -β2 expression accelerates the epithelial to mesenchymal transition in triple-negative breast cancer cells.
Kim S; Lee J; Jeon M; Nam SJ; Lee JE
Cytokine; 2015 Sep; 75(1):151-8. PubMed ID: 26088755
[TBL] [Abstract][Full Text] [Related]
38. MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAF
Sale MJ; Balmanno K; Saxena J; Ozono E; Wojdyla K; McIntyre RE; Gilley R; Woroniuk A; Howarth KD; Hughes G; Dry JR; Arends MJ; Caro P; Oxley D; Ashton S; Adams DJ; Saez-Rodriguez J; Smith PD; Cook SJ
Nat Commun; 2019 May; 10(1):2030. PubMed ID: 31048689
[TBL] [Abstract][Full Text] [Related]
39. Rhinovirus-induced MMP-9 expression is dependent on Fra-1, which is modulated by formoterol and dexamethasone.
Tacon CE; Newton R; Proud D; Leigh R
J Immunol; 2012 May; 188(9):4621-30. PubMed ID: 22461694
[TBL] [Abstract][Full Text] [Related]
40. lncRNA DRHC inhibits proliferation and invasion in hepatocellular carcinoma via c-Myb-regulated MEK/ERK signaling.
Zhuang R; Zhang X; Lu D; Wang J; Zhuo J; Wei X; Ling Q; Xie H; Zheng S; Xu X
Mol Carcinog; 2019 Mar; 58(3):366-375. PubMed ID: 30362626
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
